JP5444535B2 - 皮質カテコールアミン作動性神経伝達の調節物質としての新規な二置換フェニルピロリジン - Google Patents

皮質カテコールアミン作動性神経伝達の調節物質としての新規な二置換フェニルピロリジン Download PDF

Info

Publication number
JP5444535B2
JP5444535B2 JP2010510783A JP2010510783A JP5444535B2 JP 5444535 B2 JP5444535 B2 JP 5444535B2 JP 2010510783 A JP2010510783 A JP 2010510783A JP 2010510783 A JP2010510783 A JP 2010510783A JP 5444535 B2 JP5444535 B2 JP 5444535B2
Authority
JP
Japan
Prior art keywords
difluorophenyl
pyrrolidin
mmol
chloro
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010510783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529081A5 (enExample
JP2010529081A (ja
Inventor
ソネッソン、クラス
スワンソン、ラルス
ペッテルソン、フレドリック
ウォーターズ、ニコラス
ウォーターズ、スザンナ
Original Assignee
インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー filed Critical インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー
Publication of JP2010529081A publication Critical patent/JP2010529081A/ja
Publication of JP2010529081A5 publication Critical patent/JP2010529081A5/ja
Application granted granted Critical
Publication of JP5444535B2 publication Critical patent/JP5444535B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2010510783A 2007-06-05 2008-06-04 皮質カテコールアミン作動性神経伝達の調節物質としての新規な二置換フェニルピロリジン Expired - Fee Related JP5444535B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94199407P 2007-06-05 2007-06-05
SE0701387 2007-06-05
SE0701387-3 2007-06-05
US60/941,994 2007-06-05
PCT/EP2008/056915 WO2008148801A2 (en) 2007-06-05 2008-06-04 Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

Publications (3)

Publication Number Publication Date
JP2010529081A JP2010529081A (ja) 2010-08-26
JP2010529081A5 JP2010529081A5 (enExample) 2011-07-14
JP5444535B2 true JP5444535B2 (ja) 2014-03-19

Family

ID=39743744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010510783A Expired - Fee Related JP5444535B2 (ja) 2007-06-05 2008-06-04 皮質カテコールアミン作動性神経伝達の調節物質としての新規な二置換フェニルピロリジン

Country Status (16)

Country Link
US (1) US8188301B2 (enExample)
EP (1) EP2155671B8 (enExample)
JP (1) JP5444535B2 (enExample)
KR (1) KR20100038295A (enExample)
CN (1) CN101808987A (enExample)
AU (1) AU2008258599B2 (enExample)
BR (1) BRPI0812740A2 (enExample)
CA (1) CA2690091A1 (enExample)
CO (1) CO6251288A2 (enExample)
IL (1) IL202045A0 (enExample)
MX (1) MX2009012787A (enExample)
NZ (1) NZ581364A (enExample)
RU (1) RU2471781C2 (enExample)
UA (1) UA98783C2 (enExample)
WO (1) WO2008148801A2 (enExample)
ZA (1) ZA200908592B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008258599B2 (en) 2007-06-05 2013-06-13 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
CA2744308C (en) 2008-11-24 2017-05-30 Nsab, Filial Af Neurosearch Sweden Ab, Sverige 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
MX2011005034A (es) 2008-11-24 2011-06-16 Nsab Af Neurosearch Sweden Ab Nuevos derivados de 3-fenil-azetidina utiles como moduladores de la neurotransmision catecolaminergica cortical.
EP2367786B1 (en) * 2008-11-24 2013-01-09 NSAB, Filial af NeuroSearch Sweden AB, Sverige Novel 1 -alkyl- 3 -hydroxy- 3 -phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
WO2010071575A1 (en) * 2008-12-16 2010-06-24 Astrazeneca Ab Quaternary piperidine derivatives and uses thereof
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
JP5868324B2 (ja) * 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
KR102213609B1 (ko) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 키랄 제어
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
BR112016016400A2 (pt) 2014-01-16 2017-10-03 Wave Life Sciences Ltd Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
PT3297987T (pt) 2015-05-20 2019-06-19 Integrative Res Laboratories Sweden Ab Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical
WO2017138588A1 (ja) 2016-02-10 2017-08-17 住友化学株式会社 １－メチルピロリジン－３－オールの製造方法
EP3625213B1 (en) 2017-05-19 2023-03-08 Integrative Research Laboratories Sweden AB (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine fumarate, a process for its preparation and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2878264A (en) * 1959-03-17 Substituted amino alcohols
DE1144279B (de) 1957-09-26 1963-02-28 Robins Co Inc A H Verfahren zur Herstellung von 3-Aryl-3-hydroxypyrrolidinen und deren Salzen
US3118907A (en) * 1961-08-14 1964-01-21 Mead Johnson & Co 3-substituted-3-pyrrolidinols
BE704683A (enExample) 1966-11-07 1968-02-15
US3635982A (en) * 1969-04-08 1972-01-18 American Home Prod Amino-substituted-quinoxalinyloxazolidines and -oxazines
US5128362A (en) * 1988-01-15 1992-07-07 Abbott Laboratories 1-aminomethyl-1,2,3,4-tetrahydronaphthalenes
DE3802175A1 (de) 1988-01-26 1989-08-03 Hoechst Ag N-phenylbenzamide und n-phenylbenzamidoxime, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als schaedlingsbekaempfungsmittel
DE3835291A1 (de) * 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
US5444083A (en) * 1989-02-03 1995-08-22 Eisai Co., Ltd. Pyrrolidine compound and pharmaceutical use
WO1992018475A2 (en) * 1991-04-17 1992-10-29 The Upjohn Company Substituted phenylazacycloalkanes as cns agents
EP0586229A1 (en) * 1992-09-01 1994-03-09 Zeneca Limited 3-Hydroxy-3-(subst-akyl)-pyrrolidines as 5-lipoxygenase inhibitors
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
EP1098892A1 (en) 1998-07-20 2001-05-16 MERCK PATENT GmbH Biphenyl derivatives
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US20020169155A1 (en) * 1998-09-04 2002-11-14 Millennium Pharmaceuticals, Inc. Chemokine receptor anagonists and methods of use therefor
DE19840611A1 (de) * 1998-09-05 2000-03-09 Klaus Wanner GABA-uptake-Inhibitoren mit Pyrrolidinstruktur
AU5025600A (en) 1999-05-17 2000-12-05 Foxboro Company, The Process control configuration system with parameterized objects
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
SE0401465D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
US7700587B2 (en) * 2004-09-07 2010-04-20 Florida A&M University Haloperidol analogs
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
JP2008540395A (ja) 2005-05-03 2008-11-20 ファイザー・インク アミドレソルシノール化合物
WO2007053145A1 (en) 2005-11-04 2007-05-10 Florida A & M University Haloperidol analogs
CA2626220A1 (en) 2005-12-21 2007-06-28 Janssen Pharmaceutica N.V. Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases
AU2008258597A1 (en) 2007-06-05 2008-12-11 Nsab, Filial Af Neurosearch Sweden Ab, Sverige New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
AU2008258599B2 (en) 2007-06-05 2013-06-13 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

Also Published As

Publication number Publication date
NZ581364A (en) 2011-10-28
US8188301B2 (en) 2012-05-29
US20100179211A1 (en) 2010-07-15
WO2008148801A3 (en) 2009-01-29
AU2008258599B2 (en) 2013-06-13
RU2009143104A (ru) 2011-07-20
EP2155671B1 (en) 2017-12-20
CN101808987A (zh) 2010-08-18
IL202045A0 (en) 2010-06-16
WO2008148801A2 (en) 2008-12-11
BRPI0812740A2 (pt) 2016-07-19
CA2690091A1 (en) 2008-12-11
JP2010529081A (ja) 2010-08-26
EP2155671B8 (en) 2018-02-21
KR20100038295A (ko) 2010-04-14
CO6251288A2 (es) 2011-02-21
EP2155671A2 (en) 2010-02-24
ZA200908592B (en) 2011-02-23
AU2008258599A1 (en) 2008-12-11
WO2008148801A8 (en) 2009-12-10
MX2009012787A (es) 2009-12-15
UA98783C2 (en) 2012-06-25
RU2471781C2 (ru) 2013-01-10

Similar Documents

Publication Publication Date Title
JP5444535B2 (ja) 皮質カテコールアミン作動性神経伝達の調節物質としての新規な二置換フェニルピロリジン
US9035073B2 (en) 3-phenyl-3-methoxy-pyrrolidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
AU2012244867A1 (en) Novel modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission
EP2155669B1 (en) New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
EP1963268B1 (en) Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission
US20110257148A1 (en) Novel 1-alkyl-3-hydroxy-3-phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
JP5621087B2 (ja) 皮質のカテコールアミン作動性神経伝達のモジュレーターとして有用な新規な３−フェニル−アゼチジン誘導体
JP2018520100A (ja) 皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規なアゼチジン誘導体
HK1147260A (en) Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130513

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131029

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20131126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131126

R150 Certificate of patent or registration of utility model

Ref document number: 5444535

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees